Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

David Ho

Urology Houston, TX Medical Doctor

NPI 1215937586 CMS profile 10482

6560 Fannin St Ste 1554, Houston, TX 77030

Open in the dashboard

General payments

$4,523

215 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, David Ho of Houston, TX is reported in the CMS Open Payments database as having received $4,523 across 215 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 62nd percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $762 26
2024 General $525 21
2023 General $545 27
2022 General $866 42
2021 General $808 41
2020 General $494 30
2019 General $523 28

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Ho
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to David Ho were reported at $762. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year David Ho Urology median Middle half National median
2019 $523 $480 $147–$1,201 $163
2020 $494 $246 $87–$645 $114
2021 $808 $358 $111–$1,000 $132
2022 $866 $476 $143–$1,263 $149
2023 $545 $560 $168–$1,461 $160
2024 $525 $563 $170–$1,464 $164
2025 $762 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Astellas Pharma US Inc $1,068 47 payments
  2. Pfizer Inc. $594 32 payments
  3. Sumitomo Pharma America, Inc. $384 21 payments
  4. Janssen Biotech, Inc. $310 14 payments
  5. Abbott Laboratories $181 4 payments
  6. 180 Medical, Inc. $149 7 payments
  7. Urovant Sciences Inc $132 7 payments
  8. Bayer HealthCare Pharmaceuticals Inc. $124 8 payments
  9. Boston Scientific Corporation $124 6 payments
  10. ConvaTec Inc. $116 5 payments
  11. Other $1,340 64 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,046 205 payments
  2. Education $477 10 payments
Products named General payments · program years 2019–2025
  1. XTANDI $979 57 payments
  2. GEMTESA $418 22 payments
  3. ORGOVYX Oncology $347 14 payments
  4. MYRBETRIQ $288 18 payments
  5. ERLEADA $274 13 payments
  6. PROCLAIM $181 4 payments
  7. XIAFLEX $162 9 payments
  8. ORGOVYX Hormone Therapy $157 9 payments
  9. TALZENNA $150 5 payments
  10. AVEED $148 8 payments
  11. Other $1,947 97 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 23 drugs

Part D claims

2,035

Median for Urology: 1,053

Drug cost

$195,855

Median for Urology: $101,464

Branded share of claims

24.5%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gemtesa Vibegron Brand 91 $77,047
Myrbetriq Mirabegron Brand 91 $68,117
Tamsulosin Hcl Generic 750 $12,082
Jatenzo Testosterone Undecanoate Brand 12 $12,039
Xyosted Testosterone Enanthate Brand 17 $10,226
Finasteride Generic 238 $3,309
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 60 $1,944
Solifenacin Succinate Generic 56 $1,734
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 103 $1,421
Ciprofloxacin Hcl Generic 153 $1,307

The 10 drugs with the highest cost, of 23 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 64 billing codes

Paid by Medicare

$493,617

Of which drugs: $14,371

Medicare patients

1,266

Average age 72

Services billed

8,504

450 women, 816 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Chronic kidney disease 67%
Ischemic heart disease 53%
Diabetes 50%
Arthritis 43%
Heart failure 41%
Atrial fibrillation 32%
Depression 26%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Leuprolide acetate (for depot suspension), 7.5 mg J9217 Office 13 90 $12,767

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ORGOVYX
  • Sumitomo Pharma America, Inc. $63
  • PFIZER INC. $8
$71 — —
GEMTESA
  • Sumitomo Pharma America, Inc. $67
$67 91 —
XTANDI
  • Astellas Pharma US Inc $35
  • PFIZER INC. $8
$43 — —
Trelstar
  • Verity Pharmaceuticals Inc. $37
$37 — —
ADSTILADRIN
  • Ferring Pharmaceuticals Inc. $23
$23 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

215 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record